Naltrexone for heroin dependence treatment in St. Petersburg, Russia
Received 13 July 2003; received in revised form 4 December 2003; accepted 5 February 2004.
Abstract
Naltrexone may be more effective for treating opioid (heroin) dependence in Russia than in the U.S. because patients are mostly young and living with their parents, who can control medication compliance. In this pilot study we randomized 52 consenting patients who completed detoxification in St. Petersburg to a double blind, 6-month course of biweekly drug counseling and naltrexone, or counseling and placebo naltrexone. Significant differences in retention and relapse favoring naltrexone were seen beginning at 1 month and continuing throughout the study. At the end of 6 months, 12 of the 27 naltrexone patients (44.4%) remained in treatment and had not relapsed as compared to 4 of 25 placebo patients (16%; p<0.05). Since heroin dependence is the main way HIV is being spread in Russia, naltrexone is likely to improve treatment outcome and help reduce the spread of HIV if it can be made more widely available.
aSt. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
bUniversity of Pennsylvania, Department of Psychiatry and Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
Corresponding author. University of Pennsylvania, Department of Psychiatry and Veterans Affairs Medical Center; Treatment Research Institute, 600 Public Ledger Building, 150 S. Independence Mall (W) Philadelphia, PA 19106, USA